Postpartum Pulmonary Embolism and Outcome, Experience at a Tertiary Centre

Prashiddha Bikram Kadel

doi:10.47191/ijmra/v4-i11-04

Abstract

Pulmonary embolism is a fatal condition leading to loss of life if delay in treatment and diagnosis is present. Every year many patients present to tertiary centre with features suggestive of pulmonary embolism and a large proportion belong to postpartum pulmonary embolism. Due to the hyper coagulable state during pregnancy, pregnant and postpartum females are more prone to pulmonary embolism. Methods: All the patients records who were diagnosed as pulmonary embolism admitted in Manmohan Cardiothoracic Vascular and Transplant Center between Baisakh 2070 to Poush 2077 were investigated and observational cross-sectional study of patient population on the basis of demography, parity, day of diagnosis of postpartum Pulmonary embolism and modes of delivery was done.

Highlights

Pulmonary embolism is a fatal condition leading to loss of life if delay in treatment and diagnosis is present
Postpartum pulmonary embolism represents a fraction of pulmonary embolism
Primigravida are more likely to present with postpartum pulmonary embolism with susceptible time within 4 weeks of delivery

Summary

Introduction

Pulmonary embolism is a fatal condition leading to loss of life if delay in treatment and diagnosis is present. Methods: All the patients records who were diagnosed as pulmonary embolism admitted in Manmohan Cardiothoracic Vascular and Transplant Center between Baisakh 2070 to Poush 2077 were investigated and observational cross-sectional study of patient population on the basis of demography, parity, day of diagnosis of postpartum Pulmonary embolism and modes of delivery was done. The time of presentation of patients with pulmonary embolism who had undergone lower section cesarean section was (4.18± 2.75 days VS 14.25±3.7 days) in comparison to normal vaginal delivery. Besides decreased serum plasminogen activator inhibitor-1 and placental PAI-2 inhibits fibrinolysis In addition to this heterozygous carriers of factor V1 and prothrombin mutation 2, antiphospholipid syndrome present with high risk of thrombosis 3.

Objectives

Methods

Results

Discussion

Conclusion